TCRT

1.6906.29%
CH

Carl H. June

Chairman of Scientific Advisory Board

Dr. Carl H. June, Ph.D., M.D., is Member of Scientific Advisory Board of TILT Biotherapeutics Ltd. Dr. June is Member of Scientific Advisory Council of Cancer Research Institute, Inc. He is Member of External Advisory Board of WIRB-Copernicus Group, Inc. Dr. June is Member of Research Advisory Board of Candel Therapeutics, Inc. from September 2025. He is Member of Scientific Advisory Board of Vittoria Biotherapeutics, Inc. Dr. June is Chair of Scientific Advisory Board of Hangzhou Qihan Biotechnology Co. Ltd. from December 2024. Dr. June serves as a Member of External Advisory Board of WCG Clinical Inc. Dr. June is Member of Scientific Advisory Board of Shinobi Therapeutics, Inc. since December 2023. Dr. June is Founder of BlueWhale Bio Inc. He is Member of Scientific Advisory Board of Carisma Therapeutics, Inc. He is a pioneer in developing the first U.S. Food and Drug Administration (FDA)-approved CAR-T cell therapy. He is Member of Advisory Board at Dispatch Biotherapeutics, Inc. Dr. Carl serves as Member of Advisory Board at Genscript Biotech Corporation from 2024. He is Member of Scientific Advisory Board at GenScript Biotech Corporation since March 2024. He is Member of Scientific Advisory Board at Treadwell Therapeutics Inc. from February 2024. He served as Member of Gene Therapy Advisory Board at WIRB-Copernicus Group, Inc until 2023. He is Member of the Scientific Advisory Board of Replay Holdings, LLC. He served as Scientific Advisory Board Member at Capstan Therapeutics, Inc. He served as Member of Scientific Advisory Board of Cartography Biosciences Inc. He is Member of the Scientific Advisory Board of Danaher Corporation from January 2022. He has been Founding Advisor at Verismo Therapeutics, Inc. He serves as Member of Scientific Advisory Board at CellCarta (formerly, CellCarta Precision Medicine Inc. (formerly known as Caprion Proteomics, Inc.). He serves as Member of Scientific Advisory Board at Poseida Therapeutics, Inc. since March 2021 and also serves as its Chairman of Cell Therapy since 2023 and had been its Chairman of Immuno-Oncology Scientific Advisory Board since 2021 until 2023. He serves as a Member of Scientific Advisory Board at Bluesphere Bio, Inc. He serves as Member of Board of Advisors at Cellares Corp. He serves as Member of Scientific Advisory Board at Cabaletta Bio, Inc. since August 2020. He serves as Chairman of Scientific Advisory Board at Alaunos Therapeutics, Inc. (formerly known as ZIOPHARM Oncology, Inc.) since June 2020. He was the Member of Scientific Advisory Board at Sunesis Pharmaceuticals, Inc. (formerly known as Viracta Therapeutics, Inc.) since September 2018 until February 2025. Dr. June Co-Founded Tmunity Therapeutics, Inc. and serves as its Chief Scientific Advisor. He is a Senior Advisor for the healthcare team. He is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine, Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, Medicine Director of Translational Research Programs and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. He serves as Director at The Leonard and Madlyn Abramson Family and Cancer Research Institute and at Translational Research at the Abramson Cancer Center at the University of Pennsylvania. He has been Scientific Founder at TMune Therapeutics, Inc. since 2008. He served as Scientific & Medical Advisor at MaxCyte, Inc. since September 2006. He is an Investigator of the Abramson Family Cancer Research Institute. He rose to Professor in the Departments of Medicine and Cell and Molecular Biology at the Uniformed Services University for the Health Sciences in Bethesda, Maryland as of February 1, 1999. He serves as the Vice Chairman of the Department of Molecular and Cellular Engineering at the University of Pennsylvania. He was a Scientific Founder of Xcyte. He serves as Member of Scientific Advisory Board at TMune Therapeutics, Inc. He has been Member of Scientific Advisory Board at Cytosorbents Corporation since March 2017. He serves as Member of Scientific Advisory Board at GBP Capital (alternate name, Greenwich Biotech Partners). He serves as a Member of Scientific Advisory Board of Celldex Therapeutics, Inc. and Immune Design Corp. He serves as a Member of Medical & Clinical Advisory Board at Cerulean Pharma Inc. He serves as a Member of the Medical Advisory Board and Member of the Scientific Advisory Board at VIRxSYS Corporation. He serves as a Member of Scientific Advisory Board at GlobeImmune, Inc. He served as Independent Non-Executive Director at AC Immune SA since November 20, 2020 until 2026. He served as Member of Scientific Advisory Board of Advaxis, Inc. He served as Member of Scientific Advisory Board of Cell Genesys, Inc. Xcyte Therapies Inc. He founded the Immune Cell Biology Program and served as Head of the Department of Immunology at the Naval Medical Research Institute from 1990 to 1995. He maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy. He has published more than 350 manuscripts and is the recipient of numerous prizes and honors, including election to the Institute of Medicine in 2012 and the American Academy of Arts and Sciences in 2014, the William B. Coley award, the Richard V. Smalley Memorial Award from the Society for Immunotherapy of Cancer, the AACR-CRI Lloyd J. Old Award in Cancer Immunology, the Philadelphia Award in 2012, the Taubman Prize for Excellence in Translational Medical Science in 2014 (shared w S. Grupp, B. Levine, D. Porter), the Paul Ehrlich and Ludwig Darmstaedter Prize (shared w J. Allison), the Novartis Prize in Immunology (shared w Z. Eshaar and S. Rosenberg), the Karl Landsteiner Memorial award, the Debrecen Award and a lifetime achievement award from the Leukemia and Lymphoma Society. He is Board certified in Internal Medicine and Medical Oncology. He had graduate training in Immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland from 1978 to 1979 and post-doctoral training in transplantation biology with Dr. E. Donnell Thomas and John Hansen at the Fred Hutchinson Cancer Research Center in Seattle from 1983 to 1986. He is an MD and a graduate of the United States Naval Academy in Annapolis and Baylor College of Medicine in Houston, 1979.

Positions